Metraipolis › archive › dc_44136ca42cb3
Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors — Europe PMC PMID:41520162
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41520162
- DOI
- 10.1093/oncolo/oyag003
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T08:48:14.889Z
- SHA-256 of the archived text
09bede8a4e991061ba61e8969b40714e1494fb1c946cd85886c3d8550552b662- Stable URL of this page
https://metraipolis.com/documento/dc_44136ca42cb3
How to cite
Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors — Europe PMC PMID:41520162 — Europe PMC (en), https://europepmc.org/article/MED/41520162 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_44136ca42cb3 (Metraipolis archive dc_44136ca42cb3, sha256 09bede8a4e991061ba61e8969b40714e1494fb1c946cd85886c3d8550552b662)
BibTeX
@misc{dc44136ca42cb3,
title = {Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors — Europe PMC PMID:41520162},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41520162},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_44136ca42cb3; sha256 09bede8a4e991061ba61e8969b40714e1494fb1c946cd85886c3d8550552b662},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41520162. Agents can read the archived copy with the MCP tool read_document.